CD28 and cancer: Upregulation of PD-L1 on DCs was seen after contact with CD40L:CD28 CSP-expressing T cells suggesting that reprogramming of tumor-conditioned myeloid cells (85) together with checkpoint inhibition could be the next step forward to improve cancer immunotherapy (86, 87).